(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/193878 A1

(51) International Patent Classification:
C07D 519/00 (2006.01) *C07D 471/04* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/US2025/019643

(22) International Filing Date:
12 March 2025 (12.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/564,090	12 March 2024 (12.03.2024)	US
63/669,038	09 July 2024 (09.07.2024)	US
63/709,182	18 October 2024 (18.10.2024)	US

(71) Applicant: **COGENT BIOSCIENCES, INC.** [US/US]; 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451 (US).

(72) Inventors: **SMITH, Aaron Christopher**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **SALITURO, Leah J.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **MALINKY, Cori A.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **JALLURI, Ravi Kumar**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **CARLSON, Paul**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **ALLEY, Kimberly**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **FULTON, Jennifer**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US). **NIMAN, Scott, W.**; c/o Cogent Biosciences, 4840 Pearl E Circle, Suite 100, Boulder, Colorado 80301 (US).

(74) Agent: **KANEKO, Miho** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: KRAS INHIBITORS

Formula (I):



(57) Abstract: A compound having the following structure of Formula (I): or a stereoisomer of the compound, tautomer of the compound, or salt thereof, wherein R^1, R^2, L, X, Y, A, and B are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.

WO 2025/193878 A1